

Special Issue

Cellular and Viral Immunology of HIV-1 Infection

Message from the Guest Editors

The human immunodeficiency virus (HIV) continues to be a global threat since its emergence in 1981. Even though an enormous amount of research has been carried out to understand the life cycle of the virus, HIV remains a mystery. There is currently no effective cure, but with proper medical care, HIV can be controlled. If left untreated, it can lead to AIDS (acquired immunodeficiency syndrome). HIV attacks and weakens the body's immune system. It evades T4 lymphocyte, which is the key component for generating and regulating the immune response, and many other cell types, such as monocytes/macrophages. HIV uses its envelope glycoprotein binds to host cell receptors CD4 and CCR5/CXCR4, driving the virus' entry into host cells to further replicate and transmit using the host cell machinery. It is imperative that studies on HIV continue and are shared. This Special Issue is focused on the recent advances made in this field. We invite you to contribute with an original report or review to highlight the Cellular and Viral Immunology of HIV-1 Infection.

Guest Editors

Dr. Saumya Anang

Microbiology, Dana-Farber Cancer Institute, Harvard Medical School,
450 Brookline Ave., Boston, MA 02215, USA

Dr. Qian Wang

Irving Medical Center, Columbia University, 701 W. 168 St, 11th Floor,
New York, NY 10032, USA

Deadline for manuscript submissions

closed (12 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/164767

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).